Current Issue
Volume 14, Issue 5 - 2026 (May 2026 Issue 05 )
Issue Details:
Volume 14 Issue 5 (May 2026 Issue 05)Issue Description:
Welcome to the 2026 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.
We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.
As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.
Dr H J Patel
Editor-in-Chief
American Journal of Pharmacy and Health Research
Articles in This Issue
INVESTIGATING CLINICAL OUTCOMES OF ALPHA-BLOCKER MONOTHERAPY COMPARED TO COMBINED 5-ARI PROTOCOLS IN THE CONTEXT OF BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a common condition in elderly men characterized by prostate enlargement, resulting in lower urinary tract symptoms (LUTS) that significantly impact quality of life. Pharmacological management includes alpha-blockers and 5-alpha reductase inhibitors (5-ARIs). To compare the clinical outcomes of alpha-blocker monotherapy with combination therapy in patients with BPH. A 6-month prospective comparative study was conducted in 100 patients with moderate to severe BPH. Patients were treated with either alpha-blocker monotherapy or combination therapy (alpha-blocker with 5-ARI). Clinical outcomes were evaluated using the International Prostate Symptom Score (IPSS) at baseline and after 3 months. Statistical analysis was performed with significance set at p<0.05. Both treatment groups showed improvement in LUTS. However, combination therapy resulted in a greater reduction in IPSS scores and improved clinical response compared to monotherapy, particularly in patients with more severe symptoms. Combination therapy provides superior clinical outcomes and may offer better long-term disease control, while monotherapy remains effective for rapid symptomatic relief. KEYWORDS: Benign prostatic hyperplasia, alpha-blockers, 5-alpha reductase inhibitors, combination therapy, IPSS score, prostate volume.
Contributors:
Control Drug Delivery System – Recent Technological Developments
The drug delivery system enables the release of the active pharmaceutical ingredient to achieve a desired therapeutic response. Conventional drug delivery systems (tablets, capsules, syrups, ointments, etc.) suffer from poor bioavailability and fluctuations in plasma drug level and are unable to achieve sustained release. Without an efficient delivery mechanism, the whole therapeutic process can be rendered useless. Moreover, the drug has to be delivered at a specified controlled rate and at the target site as precisely as possible to achieve maximum efficacy and safety. Controlled drug delivery systems are developed to combat the problems associated with conventional drug delivery. There has been a tremendous evolution in controlled drug delivery systems from the past two decades ranging from macro scale and nano scale to intelligent targeted delivery. The most recent breakthroughs in controlled drug delivery systems (2025–2026) include wirelessly controlled bioelectronic devices, advanced nanocarriers, and smart polymers that allow precise, patient-specific dosing and targeted release. These innovations aim to improve treatment accuracy, reduce side effects, and enhance patient compliance. Recent advancements in controlled drug delivery systems (CDDS) focus on enhancing precision, patient compliance, and efficacy through nanotechnology, stimuli-responsive materials, and smart, wearable devices. Key developments include lipid nanoparticles (LNPs) for nucleic acid delivery, stimuli-responsive systems that release drugs based on pH or temperature, wearable pumps, and microneedles for painless, transdermal administration. The paper concludes with the challenges faced and future directions in controlled drug delivery. Key-words - controlled bioelectronic devices, stimuli-responsive systems, wearable pumps, intelligent targeted delivery, etc.